{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:25Z","timestamp":1787063065860,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Taisho Pharmaceutical Co. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s13300-021-01014-0","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T08:29:08Z","timestamp":1613723348000},"page":"863-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Luseogliflozin in Patients with Type\u00a02 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4690-9722","authenticated-orcid":false,"given":"Hiroaki","family":"Seino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"1014_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ajg.2018.08.003","volume":"19","author":"AE Hamed","year":"2018","unstructured":"Hamed AE, Elsahar M, Elwan NM, et al. Managing diabetes and liver disease association. Arab J Gastroenterol. 2018;19:166\u201379.","journal-title":"Arab J Gastroenterol"},{"key":"1014_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1871530318666181116111945","volume":"19","author":"AE Hamed","year":"2019","unstructured":"Hamed AE, Elwan N, Naguib M, et al. Diabetes association with liver diseases: an overview for clinicians. Endocr Metab Immune Disord Drug Targets. 2019;19:274\u201380.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"1014_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","volume":"29","author":"NC Leite","year":"2009","unstructured":"Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113\u20139.","journal-title":"Liver Int"},{"key":"1014_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/jgh.12204","volume":"28","author":"WK Chan","year":"2013","unstructured":"Chan WK, Tan AT, Vethakkan SR, Tah PC, Vijayananthan A, Goh KL. Non-alcoholic fatty liver disease in diabetics\u2013prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J Gastroenterol Hepatol. 2013;28:1375\u201383.","journal-title":"J Gastroenterol Hepatol"},{"key":"1014_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2337\/dc06-1539","volume":"30","author":"KG Tolman","year":"2007","unstructured":"Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type\u00a02 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734\u201343.","journal-title":"Diabetes Care"},{"key":"1014_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0895-4356(91)90209-R","volume":"44","author":"B Balkau","year":"1991","unstructured":"Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991;44:465\u201374.","journal-title":"J Clin Epidemiol"},{"key":"1014_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2337\/diacare.22.5.756","volume":"22","author":"R de Marco","year":"1999","unstructured":"de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type\u00a02 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756\u201361.","journal-title":"Diabetes Care"},{"key":"1014_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jdi.12316","volume":"6","author":"Y Seino","year":"2015","unstructured":"Seino Y, Inagaki N, Haneda M, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type\u00a02 diabetes mellitus. J Diabetes Investig. 2015;6:443\u201353.","journal-title":"J Diabetes Investig"},{"key":"1014_CR9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1014_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1014_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","volume":"30","author":"Y Seino","year":"2014","unstructured":"Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type\u00a02 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30:1245\u201355.","journal-title":"Curr Med Res Opin"},{"key":"1014_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/dom.12481","volume":"17","author":"R Nishimura","year":"2015","unstructured":"Nishimura R, Osonoi T, Kanada S, et al. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type\u00a02 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab. 2015;17:800\u20134.","journal-title":"Diabetes Obes Metab"},{"key":"1014_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1507\/endocrj.EJ15-0097","volume":"62","author":"Y Seino","year":"2015","unstructured":"Seino Y, Kaku K, Inagaki N, et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type\u00a02 diabetes mellitus inadequately controlled with diet and exercise. Endocr J. 2015;62:593\u2013603.","journal-title":"Endocr J"},{"key":"1014_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.clinthera.2016.01.017","volume":"38","author":"S Sakai","year":"2016","unstructured":"Sakai S, Kaku K, Seino Y, et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type\u00a02 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther. 2016;38:843\u201362.","journal-title":"Clin Ther"},{"key":"1014_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","volume":"7","author":"S Qiang","year":"2015","unstructured":"Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7:104.","journal-title":"Diabetol Metab Syndr"},{"key":"1014_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1055\/s-0042-111515","volume":"66","author":"M Kusunoki","year":"2016","unstructured":"Kusunoki M, Natsume Y, Sato D, et al. Luseogliflozin, A sodium glucose co-transporter 2 inhibitor, alleviates hepatic impairment in Japanese patients with type\u00a02 diabetes. Drug Res (Stuttg). 2016;66:603\u20136.","journal-title":"Drug Res (Stuttg)"},{"key":"1014_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hepr.13236","volume":"49","author":"Y Sumida","year":"2019","unstructured":"Sumida Y, Murotani K, Saito M, et al. Effect of luseogliflozin on hepatic fat content in type\u00a02 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial). Hepatol Res. 2019;49:64\u201371.","journal-title":"Hepatol Res"},{"key":"1014_CR18","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc11-0606","volume":"34","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type\u00a02 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015\u201322.","journal-title":"Diabetes Care"},{"key":"1014_CR19","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2169\/internalmedicine.55.6367","volume":"55","author":"S Hirose","year":"2016","unstructured":"Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y. Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in Japanese patients with type\u00a02 diabetes mellitus. Intern Med. 2016;55:3239\u201345.","journal-title":"Intern Med"},{"key":"1014_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2169\/internalmedicine.56.7196","volume":"56","author":"T Tosaki","year":"2017","unstructured":"Tosaki T, Kamiya H, Himeno T, et al. Sodium-glucose co-transporter 2 inhibitors reduce the abdominal visceral fat area and may influence the renal function in patients with type\u00a02 diabetes. Intern Med. 2017;56:597\u2013604.","journal-title":"Intern Med"},{"key":"1014_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5551\/jat.40873","volume":"25","author":"S Sugiyama","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type\u00a02 diabetes. J Atheroscler Thromb. 2018;25:467\u201376.","journal-title":"J Atheroscler Thromb"},{"key":"1014_CR22","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/dom.13061","volume":"20","author":"T Shibuya","year":"2018","unstructured":"Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type\u00a02 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. 2018;20:438\u201342.","journal-title":"Diabetes Obes Metab"},{"key":"1014_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type\u00a02 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801\u20138.","journal-title":"Diabetes Care"},{"key":"1014_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type\u00a02 diabetes patients. Diabetes Care. 2019;42:931\u20137.","journal-title":"Diabetes Care"},{"key":"1014_CR25","doi-asserted-by":"publisher","first-page":"e13335","DOI":"10.1111\/ijcp.13335","volume":"73","author":"Y Aso","year":"2019","unstructured":"Aso Y, Kato K, Sakurai S, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type\u00a02 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019;73:e13335.","journal-title":"Int J Clin Pract"},{"key":"1014_CR26","doi-asserted-by":"publisher","first-page":"32887","DOI":"10.1038\/srep32887","volume":"6","author":"X Liao","year":"2016","unstructured":"Liao X, Wang X, Li H, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor increases circulating zinc-alpha2-glycoprotein levels in patients with type\u00a02 diabetes. Sci Rep. 2016;6:32887.","journal-title":"Sci Rep"},{"key":"1014_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","volume":"13","author":"S Steven","year":"2017","unstructured":"Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370\u201385.","journal-title":"Redox Biol"},{"key":"1014_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4093\/dmj.2018.0134","volume":"43","author":"AR Hong","year":"2019","unstructured":"Hong AR, Koo BK, Kim SW, Yi KH, Moon MK. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in Korean patients with type\u00a02 diabetes mellitus in real-world clinical practice. Diabetes Metab J. 2019;43:590\u2013606.","journal-title":"Diabetes Metab J"},{"key":"1014_CR29","doi-asserted-by":"publisher","first-page":"e1704","DOI":"10.3390\/ijms18081704","volume":"18","author":"Y Nakatsu","year":"2017","unstructured":"Nakatsu Y, Kokubo H, Bumdelger B, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017;18:e1704.","journal-title":"Int J Mol Sci"},{"key":"1014_CR30","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/dom.13441","volume":"20","author":"K Jaikumkao","year":"2018","unstructured":"Jaikumkao K, Pongchaidecha A, Chueakula N, et al. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. Diabetes Obes Metab. 2018;20:2617\u201326.","journal-title":"Diabetes Obes Metab"},{"key":"1014_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","volume":"16","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Terashima M, Sasahara Y, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type\u00a02 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32.","journal-title":"Cardiovasc Diabetol"},{"key":"1014_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","volume":"44","author":"F Bonnet","year":"2018","unstructured":"Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44:457\u201364.","journal-title":"Diabetes Metab"},{"key":"1014_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2337\/dc09-0148","volume":"33","author":"E Hamaguchi","year":"2010","unstructured":"Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010;33:284\u20136.","journal-title":"Diabetes Care"},{"key":"1014_CR34","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1111\/hepr.12456","volume":"45","author":"Y Seko","year":"2015","unstructured":"Seko Y, Sumida Y, Tanaka S, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2015;45:E53-61.","journal-title":"Hepatol Res"},{"key":"1014_CR35","doi-asserted-by":"publisher","first-page":"e0146337","DOI":"10.1371\/journal.pone.0146337","volume":"11","author":"Y Honda","year":"2016","unstructured":"Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One. 2016;11:e0146337.","journal-title":"PLoS One"},{"key":"1014_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/0091270011400604","volume":"52","author":"RK Ghosh","year":"2012","unstructured":"Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type\u00a02 diabetes mellitus. J Clin Pharmacol. 2012;52:457\u201363.","journal-title":"J Clin Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s13300-021-01123-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000}}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01014-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T05:25:02Z","timestamp":1631510702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01014-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13300-021-01123-w","URL":"https:\/\/doi.org\/10.1007\/s13300-021-01123-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}